NCT04881682RecruitingPhase 2
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 28 Apr 2021
- Start date
- 1 May 2023
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- University of Ulm
- NCT number
- NCT04881682
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 20
- From 1 May 2023 to the primary completion date, 1 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment
Lab values
- Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg/l, or evidence of nitrite-positive urinary tract infection
Other
- immunoglobulin A deficiency
- Other contraindications against immunoadsorption or intravenous immunoglobulins
Who the study is looking for
- Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines
- Disease duration of 3 years or less
- Age 18 years or above
- Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Neurology, University of Ulm Coordinator of this site? Confirm its status | Ulm | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.